BridgeMD
Antibiotic Treatment Trial in Acute Coronary Syndrome
EU CTIS ID: 2025-522136-14-00
What this study is testing
To assess whether the number of clinical endpoints (MACCE) can be reduced by antibiotic treatment, targeting mainly bacteria that have in previous studies been shown to be involved in complex atherosclerotic plaques, such as those found in patients suffering from acute myocardial infarction.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Clinically diagnosed ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)
- Invasive strategy has been chosen, i.e. angiography is performed
- Age ≥18 years
- Informed consent has been obtained
- at least 3 of following high risk criteria are met (hypertension, DM, moderate renal insufficiency eGFR<60ml/min, peripheral arterial disease ASO, multivessel coronary artery disease, previous myocardial infraction, previous stroke or TIA)
You likely can't join if
- Cardiogenic shock
- On-going methotrexate medication
- Clinical diagnosis of Takotsubo syndrome
- Pregnancy
- Probable finding of SCAD (spontaneous coronary dissection)
- Definite coronary embolism
See the full eligibility criteria
- Clinically diagnosed ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)
- Invasive strategy has been chosen, i.e. angiography is performed
- Age ≥18 years
- Informed consent has been obtained
- at least 3 of following high risk criteria are met (hypertension, DM, moderate renal insufficiency eGFR<60ml/min, peripheral arterial disease ASO, multivessel coronary artery disease, previous myocardial infraction, previous stroke or TIA)
- Cardiogenic shock
- On-going methotrexate medication
- Clinical diagnosis of Takotsubo syndrome
- Pregnancy
- Probable finding of SCAD (spontaneous coronary dissection)
- Definite coronary embolism
- Severe valvular disease
- On-going bleeding or very high bleeding risk
- < 1 year life expectancy
- On-going antibiotic therapy
- Severe allergy to contrast agents or ASA
- Allergy to cephalosporin
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.